Purpose: Our preclinical studies have shown that acidic and basic fibroblastic growth factors
confer broad spectrum chemoresistance and that low concentrations (10–50 μm) of suramin …

Purpose We reported that suramin produced chemosensitization at nontoxic doses. This
benefit was lost at the∼ 10-fold higher, maximally tolerated doses (MTD). The aim of the …

Background The purpose of this study was to evaluate the potential of noncytotoxic doses of
suramin to reverse chemotherapy resistance in advanced chemonaive and chemoresistant …

Purpose In preclinical models, non-cytotoxic suramin (concentrations< 50 μM) potentiates
the activity of multiple chemotherapeutic agents. The present study evaluated the safety and …

In the search for new therapeutic concepts in lung cancer chemotherapy, suramin, a
potential anticancer drug which evades multidrug resistance, was tested in vitro on 25 lung …

Suramin inhibits the growth of non-small cell lung cancer (NSCLC) and breast cancer in vitro
by blocking the action of most known growth factors. The clinical efficacy of suramin was …

We recently reported that acidic (aFGF) and basic (bFGF) fibroblast growth factors confer a
broad spectrum chemoresistance in solid tumors, and that suramin, an inhibitor of multiple …

Suramin cytotoxicity was studied in a panel of human lung cancer cell lines by the MTT
assay. The concentrations of suramin which induced 50% growth inhibition (ic50) ranged …

PURPOSE We used population pharmacokinetic-parameter estimates and designed a fixed
dosing schedule to maintain plasma suramin concentrations between 100 and 300 …

Purpose We reported that nontoxic suramin treatments enhance the activity of chemotherapy
in preclinical models, a finding supported by the results of subsequent phase I/II trials in …